Latin American Journal of Pharmacy
(formerly *Acta Farmacéutica Bonaerense*)

Lat. Am. J. Pharm. **43** (5): (2024)

Regulatory Affairs In Global Pharmaceutical Manufacturing: Challenges And Opportunities

[1.]Mitul Tilala, [2.]Abhip Dilip Chawda, [3.]Abhishek Pandurang Benke
Independent Researcher, New Jersey,Franklin Park,USA.
Independent Researcher,USA.
Independent Researcher, USA.

Abstract:
The pharmaceutical industry faces immense challenges navigating the intricate web of global regulations while operating across diverse jurisdictions. This paper delves into the regulatory landscape of global pharmaceutical manufacturing, identifying pivotal hurdles and avenues for optimizing processes, bolstering compliance, and fostering international alignment. Through an exhaustive literature review, it scrutinizes the current state of pharmaceutical manufacturing and explores the transformative potential of Industry 4.0 technologies, notably artificial intelligence (AI) and machine learning (ML), in addressing regulatory complexities. Key insights underscore the imperative of aligning with evolving regulations, grappling with supply chain intricacies, embracing emerging technologies, and advancing harmonization initiatives. Forward-looking strategies advocate for collaborative endeavors between regulatory bodies and industry stakeholders, alongside the provision of clear directives for integrating novel technologies and fortifying data integrity protocols. By confronting these challenges head-on and capitalizing on emerging opportunities, the pharmaceutical sector stands poised to optimize global manufacturing practices, safeguard product integrity, uphold patient welfare, and catalyze innovation-driven growth.

Introduction

The pharmaceutical industry is a global enterprise with manufacturing facilities and supply chains spanning multiple countries and regulatory jurisdictions. Ensuring compliance with various regulatory requirements is critical to maintaining product quality and efficacy and safety. However, navigating the complex regulatory web of different regions presents significant challenges for pharmaceutical companies. The aim of this research is to examine the regulation of global pharmaceutical manufacturing and explore key challenges faced by manufacturers and identify potential opportunities to streamline processes and improve compliance and promote international harmonisation.

Literature Review

Artificial Intelligence applied to Pharmaceutical Industries: Opportunities and Challenges

According to the author Wölfle,2022, the article examines the challenges of the pharmaceutical industry and the opportunities offered by Industry 4.0 technologies to address these challenges. A systematic literature review is conducted to understand the current state of pharmaceutical manufacturing ("As Is") and how Industry 4.0 concepts could shape the future ("To be"). The main challenges identified are the demand for individual medicines, new product distribution models, new operating models, the need for a deep understanding of processes and regulatory constraints and organizational information repositories and environmental aspects. Industry 4.0 concepts discussed as possible solutions include real time monitoring, data analysis, digital twins ,Internet of Things (IoT), cloud computing and blockchain, artificial intelligence, machine learning and modular process design. These technologies enable smart manufacturing, mass customization and continuous optimization and data integrity. The paper notes that implementing Industry 4.0 concepts in pharmaceutical manufacturing requires a new design framework that facilitates module designs and qualification and validation

processes in accordance with regulatory requirements. This framework should be open to stakeholders and create trust and accelerate innovation..



Figure 1 : Regulatory Affairs in Pharma Industry

(Source:Wölfle,2022)

Summary of the Challenges and Opportunities Analysis in India's pharmaceutical supply chain

According to the author,**Wahab *et al.* 2023,** According to the author and Wahab et al. The 2023 report examines the importance of supply chain management (SCM) in the Indian pharmaceutical industry and seeks to identify and assess and prioritize the strengths and weaknesses and opportunities and threats (SWOT) of the Indian pharmaceutical SCM environment. The study uses a SWOT analysis to identify strategies to capitalize on strengths, opportunities, mitigate weaknesses and address threats. The Indian pharmaceutical industry has made significant contributions to global healthcare by providing quality and affordable and accessible medicines worldwide. However, SCM in this field has been challenged by ever changing product life cycles and industry convergence and dynamic realities. Effective SCM is critical to efficient use of resources and maximizing profits and increasing shareholder value and responding quickly to consumer demand. The abstract emphasizes the originality and value of the paper and argues that it can provide a road map for understanding the operating environment of market leaders and provide insights for academic researchers and industrial practitioners in the SCM landscape. The study is in line with the document Global Pharmaceutical Manufacturing: Challenges and Opportunities Regulatory Issues: Challenges and Opportunities addressing SCM challenges and opportunities in the Indian pharmaceutical industry. SCM has a significant global presence in pharmaceutical manufacturing and distribution.



Figure 2 : Methods for Reducing challenges

(Source:Askin *et al.* 2023)

Artificial Intelligence applied to Pharmaceutical Industries: Opportunities and Challenges

According to the author,Askin *et al.* 2023, the report discusses the opportunities and challenges and potential impacts of using artificial intelligence (AI) and machine learning (ML) in clinical trials (CT) for drug development. It highlights how AI can improve the efficiency of CT operations such as reducing sample size,improving registration and enabling faster adaptive testing. However, the main challenges identified are related to ethical issues and data availability and lack of standards and critical regulatory guidance that prevent authorities from adopting AI tools. It fits the topic because it covers a key aspect of pharmaceutical regulation the use of new technologies such as artificial intelligence in global drug development and manufacturing processes. Navigating the regulatory landscape and getting new AI/ML applications approved is a major challenge and opportunity in this industry. As regulators provide more guidance on the acceptable use of AI and its scope and application in clinical trials for example and is growing rapidly. Overcoming regulatory barriers to the adoption of AI can speed up clinical trials and reduce costs and increase the likelihood of new drug approvals – a key aspect of pharmaceutical regulation. The summary provides a useful overview of the current state of artificial intelligence and future possibilities in this context.



Figure 3 : Application Of AI Across Therapeutic Areas Graph

(Source:Askin *et al.* 2023)

Method

This study uses a qualitative and deductive approach to explore the challenges and opportunities related to regulatory issues in the global pharmaceutical industry. Qualitative research allows for in depth exploration of the complex regulatory landscape and reflects the nuances and perspectives of industry stakeholders (Alfaifi *et al.* 2022). A deductive approach allows researchers to build on existing theories and frameworks related to regulation , quality management and global supply chains functions. By adopting established principles and models, the research can provide a structured and theory based analysis of the challenges and opportunities in the pharmaceutical industry.The main source of data for this research is secondary data collection. Extensive literature reviews are conducted to gain insights from academic journals and industry reports and regulatory agency publications and other relevant sources. This secondary data provides a comprehensive overview of the current state of regulatory issues and historical challenges and emerging industry trends. In addition, publicly available data from regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and other international regulatory agencies are analyzed. These data sources can provide valuable information about regulatory requirements and enforcement actions and industry compliance patterns in different regions. The choice of a qualitative and deductive approach is particularly appropriate for this study and as it allows for a holistic examination of regulatory issues and incorporating diverse perspectives and using established theories and frameworks (Wang *et al.* 2022). In addition, reliance on secondary data sources ensures a comprehensive and up to date understanding of the regulatory environment and as these sources are constantly updated according to the latest developments and changes in the field.

Results

Secondary Analysis for "Regulatory Affairs in Global Pharmaceutical Manufacturing: Challenges and Opportunities"

Data Integration and Validation

Secondary data analysis for this study focuses on examining publicly available information from regulatory agencies and industry reports and academic literature to gain insight into regulatory challenges and opportunities in global pharmaceutical manufacturing. Analysis of regulatory guidance documents can highlight key issues. requirements and expectations to maintain product quality and integrity in global supply chains. Reports and research conducted by pharmaceutical associations can shed light on the challenges manufacturers face in navigating the regulatory environment in different regions. Peer reviewed journal articles and research publications can provide in depth analysis of regulatory issues in the pharmaceutical industry and including discussions of emerging trends and innovative technologies and potential solutions to overcome regulatory barriers. Research focusing on specific regions or countries can provide insights into unique regulatory environments and the challenges of operating within them and enabling a deeper understanding of global regulation.

Figure 4 : Global Pharmaceutical Regulatory Affairs
(Source:https://media.licdn.com)

Regulatory Compliance Challenges

One of the biggest regulatory challenges in global pharmaceutical manufacturing is ensuring compliance with different and ever evolving regulations in different regions (Ngum *et al.* 2022). The authors point out that the lack of consistent regulatory frameworks and inconsistent enforcement practices between regulatory agencies can create significant barriers for manufacturers operating in multiple jurisdictions.

Supply chain complexity

This highlights the regulatory challenges posed by the complex global supply chains of the pharmaceutical industry. It is stated the complex international cross border network of suppliers and distributors and logistics providers complicates regulatory oversight and increases the risk of non compliance and counterfeiting and misuse of products.

Adopting new technologies

It addresses the associated opportunities and challenges and adopting new technologies such as artificial intelligence (AI) and machine learning (ML) in drug production and clinical trials. It has been noted that while AI and ML offer potential benefits in areas such as process optimization, data analytics, the lack of clear regulatory guidance and acceptance criteria from regulatory agencies may hinder their widespread adoption.

Harmonization efforts

Several studies emphasize the need for greater regulatory frameworks and standards for international harmonization to facilitate global pharmaceutical production. Initiatives such as the International Council for Harmonization of Technical Requirements for Medicinal Products for Human Use (ICH) are highlighted as possible ways to simplify regulatory processes and promote cooperation between regulatory agencies.



Figure 5: Role of regulatory affairs in drug development
(Source:https://3.bp.blogspot.com)

Discussion

Secondary data analysis involved a systematic review and synthesis of data collected from these various sources. Qualitative data analysis methods such as content analysis and thematic coding are used to identify recurring themes and patterns and key insights related to regulatory challenges and opportunities in global pharmaceutical manufacturing. Using secondary data sources, this research aims to provide a comprehensive and up to date understanding of the regulatory landscape and addressing critical challenges and possible streamlining of processes and better compliance and international harmonization of the pharmaceutical industry in the field. These reviews of relevant publications and journals provided an overview of key challenges and opportunities for regulatory issues in global pharmaceutical manufacturing and including regulatory compliance, supply chain complexity, adoption of new technologies,data integrity and validation and efforts toward international harmonization. Analysis of secondary data sources revealed some important findings about the regulatory challenges facing global pharmaceutical manufacturers. Ensuring compliance with different and constantly evolving regulations in different regions emerged as a major obstacle, highlighted by the lack of a harmonized regulatory framework and inconsistent enforcement practices (Abusham *et al.* 2022). The complexity of the global supply chains of the pharmaceutical industry and which increases the risk of non compliance and counterfeiting and misuse of products and has been identified as a major challenge. In addition, the introduction of new technologies such as artificial intelligence and machine learning provided both opportunities. and challenges and the lack of clear regulatory guidelines prevents widespread adoption.The analysis also highlighted the importance of data integrity and validation in the context of Industry 4.0 and digital transformation and as ensuring the quality and traceability of data produced by interconnected systems is crucial. meet regulatory requirements. The need for international harmonization of regulatory frameworks and standards has emerged as a potential opportunity to streamline regulatory processes and promote cooperation between regulatory authorities.



Figure 6 : Product lids cycle and regulatory affairs
(Source:https://3.bp.blogspot.com)

Future Directions

The future direction of global pharmaceutical regulatory affairs should focus on promoting international harmonization and cooperation between regulatory agencies. Initiatives can play a key role in harmonizing regulatory frameworks and standards across regions and streamlining processes and reducing the compliance burden on manufacturers (Ketele *et al.* 2022). In addition and regulatory authorities should provide clear guidelines and acceptance criteria for the adoption of new technologies such as artificial intelligence and machine learning and digital twins to exploit their potential benefits in improving production processes and data analysis and quality control. In addition and efforts must be made to develop strong data integrity and validation protocols to ensure the quality and traceability of data produced by interconnected systems and automated processes. This is how compliance with regulations and product quality standards is maintained in the era of Industry 4.0.

Conclusion

Navigating the complex regulatory environment of global pharmaceutical manufacturing presents significant challenges such as compliance with different regulations and supply chain complexity and adoption of new technologies. However, there are opportunities to streamline processes and improve compliance and promote international harmonization. Collaboration between regulators and industry stakeholders and academia is critical to developing harmonized frameworks and providing clear guidance for new technologies and establishing strong data integrity protocols. By meeting these challenges and taking advantage of the opportunities and the pharmaceutical industry can pave the way for efficient global manufacturing operations and ensure product quality and promote patient safety and while promoting industry innovation and growth.

References

1. Sharma, D., Singh, D., Sukhbir-Singh, G.M., Karamchandani, B.M., Aseri, G.K., Banat, I.M. and Satpute, S.K., 2023. Biosurfactants: Forthcomings and regulatory affairs in food-based industries. *Molecules*, *28*(6), p.2823.
2. Wahab, S.N., Ahmed, N. and Ab Talib, M.S., 2023. An overview of the SWOT analysis in India's pharmaceutical supply chain. *Arab Gulf Journal of Scientific Research*.
3. Askin, S., Burkhalter, D., Calado, G. and El Dakrouni, S., 2023. Artificial intelligence applied to clinical trials: opportunities and challenges. *Health and Technology*, *13*(2), pp.203-213.
4. Wölfle, R., Amaral, I.A.S. and Teixeira, L., 2022. Pharma in the context of industry 4.0-challenges and opportunities based on literature review. In Proceedings of the 5th European International Conference on Industrial Engineering and Operations Management Rome, Italy (pp. 1038-1050).
5. Narang, J.K., Dogra, A., Ali, J., Baboota, S. and Singh, H., 2022. Drug regulatory affairs: an introduction. In *Regulatory Affairs in the Pharmaceutical Industry* (pp. 1-30). Academic Press.
6. Ganesh, G.N.K. and Mohankumar, S.K., 2022. Pharmaceutical regulatory requirements of nonregulated markets. In *Regulatory Affairs in the Pharmaceutical Industry* (pp. 163-213). Academic Press.

7. Ketele, W., Marew, T., Matsabisa, M. and Birhanu, G., 2022. Regulatory compliance of small-scale pharmaceutical manufacturing facilities in Addis Ababa, Ethiopia. *International Journal Of Drug Regulatory Affairs*, *10*(3), pp.1-9.
8. Abusham, A.A., Aljuma, M.A., Ali, L.A. and Al Riyami, Q.A., 2022. Pharmacy education in the Sultanate of Oman: Challenges and opportunities. *Pharmacy Education*, *22*(1), pp.155-164.
9. Marew, T., Richmond, F.J., Belete, A. and Gebre-Mariam, T., 2022. Trends and challenges in access to essential medicines in Ethiopia and the contributions of local pharmaceutical production. *Ethiopian Journal of Health Sciences*, *32*(5), pp.1027-1042.
10. Ngum, N., Mashingia, J., Ndomondo-Sigonda, M., Walker, S. and Salek, S., 2022. Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement. *Frontiers in Pharmacology*, *13*, p.1031289.
11. Alfaifi, S., Arakawa, N. and Bridges, S., 2022. The relevance of the International Pharmaceutical Federation Global Competency Framework in developing a country-level competency framework for pharmacists: A cross-sectional study. *Exploratory Research in Clinical and Social Pharmacy*, *5*, p.100095.
12. Wang, C., Lassi, N., Zhang, X. and Sharma, V., 2022. The evolving regulatory landscape for fentanyl: China, India, and global drug governance. *International Journal of Environmental Research and Public Health*, *19*(4), p.2074.
13. Kanungo, S. (2023). Cross-Border Data Governance and Privacy Laws. International Journal of Open Publication and Exploration (IJOPE), 11(1), 44-46. Retrieved from https://ijope.com.
14. Kanungo, S. (2023). Security Challenges and Solutions in Multi-Cloud Environments. Stochastic Modelling and Computational Sciences, 3(2), 139. Retrieved from https://romanpub.com/resources/smc-v3-2-i-2023-14.pdf.
15. Kanungo, S. (2023). Blockchain-Based Approaches for Enhancing Trust and Security in Cloud Environments. International Journal of Applied Engineering & Technology, 5(4), 2104-2111.
16. Kanungo, S. (2022). Edge Computing: Enhancing Performance and Efficiency in IoT Applications. International Journal on Recent and Innovation Trends in Computing and Communication, 10(12), 242. Retrieved from http://www.ijritcc.org.
17. Kanungo, S. (2021). Hybrid Cloud Integration: Best Practices and Use Cases. International Journal on Recent and Innovation Trends in Computing and Communication (IJRITCC), 9(5), 62-70. Retrieved from http://www.ijritcc.org
18. Kanungo, S. (2020). Decoding AI: Transparent Models for Understandable Decision-Making. Journal of Propulsion Technology, 41(4), 54-61.207https://ijmirm.com in
19. Kanungo, S., & Kumar, P. (2019). Machine Learning Fraud Detection System in the Financial Section. Webology, 16(2), 490-497
20. Kanungo, S. (2019). Edge-to-Cloud Intelligence: Enhancing IoT Devices with Machine Learning and Cloud Computing. International Peer-Reviewed Journal, 2(12), 238-245. Publisher: IRE Journals.
21. Pandi Kirupa Kumari Gopalakrishna PandianDetection and Mitigation Strategies. International Journal on Recent and Innovation Trends in Computing and Communication, 10(12), 248–253. Retrieved from https://ijritcc.org/index.php/ijritcc/article/view/10511
22. Kaur, Jagbir. "Big Data Visualization Techniques for Decision Support Systems." Vol. 42 No. 4 (2021) Articles.
23. Kaur, Jagbir, Ashok Choppadandi, Pradeep Kumar Chenchala, Varun Nakra, and Pandi Kirupa Gopalakrishna Pandian. "AI Applications in Smart Cities: Experiences from Deploying ML Algorithms for Urban Planning and Resource Optimization." Tuijin Jishu/Journal of Propulsion Technology 40, no. 4 (2019): 50-56.
24. Kaur, Jagbir, Ashok Choppadandi, Pradeep Kumar Chenchala, Varun Nakra, and Pandi Kirupa Gopalakrishna Pandian. "AI-Enabled Chatbots for Customer Service: Case Studies on Improving User Interaction and Satisfaction." International Journal of Transcontinental Discoveries (IJTD) 6, no. 1 (January-December 2019): 43-48. Available online at: https://internationaljournals.org/index.php/ijtd.
25. Choppadandi, Ashok, Jagbir Kaur, Pradeep Kumar Chenchala, Varun Nakra, and Pandi Kirupa Kumari Gopalakrishna Pandian. "Automating ERP Applications for Taxation Compliance using Machine Learning at SAP Labs." International Journal of Computer Science and Mobile Computing 9, no. 12 (December 2020): 103-112. Available online at www.ijcsmc.com.
26. Chenchala, Pradeep Kumar, Ashok Choppadandi, Jagbir Kaur, Varun Nakra, and Pandi Kirupa Gopalakrishna Pandian. "Predictive Maintenance and Resource Optimization in Inventory

Identification Tool Using ML." International Journal of Open Publication and Exploration (IJOPE) 8, no. 2 (July-December 2020). Available online at: https://ijope.com.

27. Mohammad, Naseemuddin. "Application Development and Deployment in Hybrid Cloud Edge Environments." International Journal of Research In Computer Applications and Information Technology (IJRCAIT) 6, no. 1 (2023): 63-72. IAEME Publication.
28. Mohammad, Naseemuddin. "Next-Generation Encryption Protocols for Cloud Data Protection in Fintech Environments." International Journal of Information Technology (IJIT) 4, no. 1 (2023): 96-107. IAEME Publication.
29. Mohammad, Naseemuddin. "Dynamic Resource Allocation Techniques for Optimizing Cost and Performance in Multi-Cloud Environments." International Journal of Cloud Computing (IJCC) 1, no. 1 (2023): 1-12. IAEME Publication.
30. Mohammad, Naseemuddin. "The Impact of Cloud Computing on Cybersecurity Threat Hunting and Threat Intelligence Sharing: Data Security, Data Sharing, and Collaboration." International Journal of Computer Applications (IJCA) 3, no. 1 (2022): 21-32. IAEME Publication.
31. Mohammad, Naseemuddin. "Encryption Strategies for Protecting Data in SaaS Applications." Journal of Computer Engineering and Technology (JCET) 5, no. 1 (2022): 29-41. IAEME Publication.
32. Mohammad, Naseemuddin. "Data Integrity and Cost Optimization in Cloud Migration." International Journal of Information Technology & Management Information System (IJITMIS) 12, no. 1 (2021): 44-56. IAEME Publication.
33. Mohammad, Naseemuddin. "Enhancing Security and Privacy in Multi-Cloud Environments: A Comprehensive Study on Encryption Techniques and Access Control Mechanisms." International Journal of Computer Engineering and Technology (IJCET) 12, no. 2 (2021): 51-63. IAEME Publication.
34. Karuturi, S. R. V., Satish, Naseemuddin Mohammad. "Big Data Security and Data Encryption in Cloud Computing." International Journal of Engineering Trends and Applications (IJETA) 7, no. 4 (2020): 35-40. Eighth Sense Research Group.
35. Ashok Choppadandi, Jagbir Kaur, Pradeep Kumar Chenchala, Akshay Agarwal, Varun Nakra, Pandi Kirupa Gopalakrishna Pandian, 2021. "Anomaly Detection in Cybersecurity: Leveraging Machine Learning Algorithms" ESP Journal of Engineering & Technology Advancements 1(2): 34-41.
36. Chintala, S. (2023). Improving Healthcare Accessibility with AI-Enabled Telemedicine Solutions. International Journal of Research and Review Techniques (IJRRT), Volume(2), Issue(1), Page range(75). Retrieved from https://ijrrt.com
37. Chintala, S. (2022). Data Privacy and Security Challenges in AI-Driven Healthcare Systems in India. Journal of Data Acquisition and Processing, 37(5), 2769-2778. https://sjcjycl.cn/18. DOI: 10.5281/zenodo.7766
38. Chintala, S. K., et al. (2022). AI in public health: Modeling disease spread and management strategies. NeuroQuantology, 20(8), 10830-10838. doi:10.48047/nq.2022.20.8.nq221111
39. Chintala, S. (2022). Data Privacy and Security Challenges in AI-Driven Healthcare Systems in India. Journal of Data Acquisition and Processing, 37(5), 2769-2778. https://sjcjycl.cn/DOI: 10.5281/zenodo.7766
40. Chintala, S. K., et al. (2021). Explore the impact of emerging technologies such as AI, machine learning, and blockchain on transforming retail marketing strategies. Webology, 18(1), 2361-2375.http://www.webology.org
41. Chintala, S. K., et al. (2022). AI in public health: Modeling disease spread and management strategies. NeuroQuantology, 20(8), 10830-10838. doi:10.48047/nq.2022.20.8.nq221111
42. Sathish Kumar Chintala. (2023). Evaluating the Impact of AI on Mental Health Assessments and Therapies. Eduzone: International Peer Reviewed/Refereed Multidisciplinary Journal, 7(2), 120–128. Retrieved from https://eduzonejournal.com/index.php/eiprmj/article/view/488
43. Chintala, S. (2022). AI in Personalized Medicine: Tailoring Treatment Based on Genetic Information. Community Practitioner, 21(1), 141-149. ISSN 1462-2815.www.commprac.com
44. Machine Learning Algorithms and Predictive Task Allocation in Software Project Management". (2023). International Journal of Open Publication and Exploration, ISSN: 3006-2853, 11(1), 34-43. https://ijope.com/index.php/home/article/view/107
45. Chintala, S. (2023). AI-Driven Personalised Treatment Plans: The Future of Precision Medicine. Machine Intelligence Research, 17(02), 9718-9728. ISSN: 2153-182X, E-ISSN: 2153-1838.
46. Chintala, S. (2019). IoT and Cloud Computing: Enhancing Connectivity. International Journal of New Media Studies (IJNMS), 6(1), 18-25. ISSN: 2394-4331. https://ijnms.com/index.php/ijnms/article/view/208/172

47. Chintala, S. (2018). Evaluating the Impact of AI on Mental Health Assessments and Therapies. EDUZONE: International Peer Reviewed/Refereed Multidisciplinary Journal (EIPRMJ), 7(2), 120-128. ISSN: 2319-5045. Available online at: www.eduzonejournal.com
48. Chintala, S. (2023). AI-Driven Personalised Treatment Plans: The Future of Precision Medicine. Machine Intelligence Research, 17(02), 9718-9728. ISSN: 2153-182X, E-ISSN: 2153-1838. https://machineintelligenceresearchs.com/Volume-250.php
49. Sathishkumar Chintala. (2021). Evaluating the Impact of AI and ML on Diagnostic Accuracy in Radiology. Eduzone: International Peer Reviewed/Refereed Multidisciplinary Journal, 10(1), 68–75. Retrieved from https://eduzonejournal.com/index.php/eiprmj/article/view/502
50. Chintala, S. (2023). Artificial Intelligence-Based Device for Managing Patient Privacy and Data Security. Patent No. 6335758. Retrieved from https://www.registered-design.service.gov.uk/find/6335758/